Salesforce likely to offer up 'strong' results, guidance: Wedbush
Salesforce (NYSE:CRM) is set to report fiscal third-quarter results tomorrow after the close of trading, and Wedbush ...
Wedbush upgrades Voyager to Outperform on pipeline progress
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...
Snowflake Stock Rises as Wedbush Notes AI 'Sweet Spot' in Upgrade
Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...
Critics said Musk 'overpaid' for Twitter. Thanks to Trump and xAI, it could actually be a steal.
The billionaire was panned for overspending on Twitter, but the platform is winning him favor with Donald Trump and ...
Seeking Alpha2d
Wedbush assumes coverage of Voyager with outperform rating
Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...
Tech Stocks Set For Strong Santa Rally As Wall Street Looks For An End To 'Regulatory Spider Web' In The Trump Era, Says Dan Ives
Major technology stocks are positioned for a strong year-end rally as artificial intelligence initiatives accelerate and ...
Kioxia, SanDisk filings illustrate value of Western Digital split, says Wedbush
Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...
Expect Santa Tech rally into year-end, Wedbush says
Investing.com -- Wedbush analysts expect tech stocks to end the year on a positive note with a “Santa rally,” citing positive catalysts including deregulation under Donald Trump’s second term and ...
Tesla's AI Push Could Pave Way for $2 Trillion Valuation, Wedbush Says
A potential Trump administration may ease regulations for self-driving vehicles, accelerating Tesla's progress ...
Tesla Stock Finished Black Friday on a High Note
The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...
Business Insider3d
Wedbush upgrades Voyager to Outperform on pipeline progress
Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...